Tenax Therapeutics, Inc. (TENX) stock

TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$1.62+0.01 (+0.62%)

Close on Nov 13, 2026Market cap $60.63MP/E –Yield –

Tenax Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Tenax Therapeutics's EV/EBITDA was 68.9× on Jan 31, 2024.

Period	Period end	Value	Change (pts)
2024	Jan 31, 2024	68.9×	−48.5
2023	Dec 29, 2023	117.3×	−692.5
2022	Jan 31, 2022	809.8×	–

Parsed from the XBRL in Tenax Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-80 reverse split on Jan 3, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TENX.

Advertisement
300 × 250

See a number that looks wrong?